- TWD2.95bn
- TWD2.65bn
- TWD1.68bn
- 83
- 50
- 88
- 90
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.69 | ||
| Price to Tang. Book | 1.73 | ||
| Price to Free Cashflow | 12.22 | ||
| Price to Sales | 1.72 | ||
| EV to EBITDA | 16.42 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 4.91% | ||
| Return on Equity | 6.28% | ||
| Operating Margin | 5.34% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | TWDm | 2,198.86 | 2,005.34 | 2,131.66 | 2,244.18 | 1,676.54 | 1,891 | n/a | -3.88% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -18.16 | -19.68 | +120.97 | +5.27 | -36 | -19.2 | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
APEX BIOTECHNOLOGY CORP is a Taiwan-based company principally engaged in the research, development, manufacture and distribution of testing strips, electrode testing strips and tester suites. The Company primarily provides testing strips and monitoring systems, including blood glucose monitoring systems, uric acid monitoring systems, pesticide residue detection systems, lactate monitoring systems and hemachrome testing systems, among others. Its blood glucose monitoring systems and uric acid monitoring systems are mainly used by patients, doctors and nurses in hospitals and clinics. The Company distributes its products in domestic market and to overseas markets, including the Americas, Europe and the rest of Asia.
Directors
- Yanshi Shen CHM
- Yingxiang Zhu FID
- Mengwen Yang DGM
- Zhengming Bai IND
- Jinchang Bao IND
- Yonglu Cai IND
- Yiyun Chi IND
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- December 2nd, 1997
- Public Since
- September 17th, 2001
- No. of Shareholders
- 31,753
- No. of Employees
- 641
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Taiwan Stock Exchange- Shares in Issue
- 99,950,000
- Address
- No. 7, HSINCHU, 300
- Web
- https://www.apexbio.com.tw/
- Phone
- +886 35641952
- Contact
- Chunhui Wu
- Auditors
- Deloitte & Touche LLP
Upcoming Events for 1733
Similar to 1733
Wellell
Taiwan Stock Exchange
Bionime
Taiwan Stock Exchange
CHC Healthcare
Taiwan Stock Exchange
Excelsior Medical Co
Taiwan Stock Exchange
Lead Data
Taiwan Stock Exchange
FAQ
As of Today at 19:45 UTC, shares in Apex Biotechnology are trading at TWD29.50. This share price information is delayed by 15 minutes.
Shares in Apex Biotechnology last closed at TWD29.50 and the price had moved by +8.06% over the past 365 days. In terms of relative price strength the Apex Biotechnology share price has outperformed the FTSE Developed Asia Pacific Index by +2.52% over the past year.
The overall consensus recommendation for Apex Biotechnology is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Apex Biotechnology dividend yield is 3.73% based on the trailing twelve month period.
Last year, Apex Biotechnology paid a total dividend of TWD1.10, and it currently has a trailing dividend yield of 3.73%. We do not have any data on when Apex Biotechnology is to next pay dividends.
We do not have data on when Apex Biotechnology is to next pay dividends. The historic dividend yield on Apex Biotechnology shares is currently 3.73%.
To buy shares in Apex Biotechnology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of TWD29.50, shares in Apex Biotechnology had a market capitalisation of TWD2.95bn.
Here are the trading details for Apex Biotechnology:
- Country of listing: Taiwan
- Exchange: TAI
- Ticker Symbol: 1733
Based on an overall assessment of its quality, value and momentum Apex Biotechnology is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Apex Biotechnology. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -7.86%.
As of the last closing price of TWD29.50, shares in Apex Biotechnology were trading -10.39% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Apex Biotechnology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at TWD29.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Apex Biotechnology's management team is headed by:
- Yanshi Shen - CHM
- Yingxiang Zhu - FID
- Mengwen Yang - DGM
- Zhengming Bai - IND
- Jinchang Bao - IND
- Yonglu Cai - IND
- Yiyun Chi - IND